UCB sells to Adams Respiratory Therapeutics Delsym cough surpressants
29-May-2006
The financial terms of the agreement consist of a one-time, upfront payment to UCB of 122 million U.S. dollars, royalties for a period of 5 years based on sales and a standard manufacturing supply agreement with a "cost-plus" structure.
Most read news
Organizations
UCB
Adams Respiratory Therapeutics
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.